Summary
A membrane suspension prepared from rat brain was able to bind the potent muscarinic antagonist quinuclidinyl benzilate (QNB). The KD for binding was 0.48 nM and Bmax was 1.42 pmol/mg protein. Atropine competitively inhibited the binding of tritiated QNB to muscarinic receptors. This new radioreceptor assay (RRA) for atropine has been compared with a radioimmunoassay (RIA) for atropine. The RRA measures only the active component of atropine, 1-hyscyamine and in this respect it differs from the RIA. As little atropine as 1.25 ng/ml (4.33 nmol/l) in a 25 µl serum sample could be reliably assayed by the RRA. Using both assay techniques the pharmacokinetics of atropine was studied after a single 0.02 mg/kg i.v. dose given to 8 anaesthetized patients. The half-life calculated by the RRA was 3.7±2.3 h (m ± SD) and by the RIA 4.3±1.7 h. Both the volume of distribution and the total clearance were higher according to the RRA than the RIA: 3.9±1.5 vs 1.7±0.71/kg and 15.4±10.3 vs 5.9±3.6 ml/min/kg, respectively. The AUC measured by the RRA and RIA was 29.8±18.9 and 103.9±110.7 µg·h/l, respectively. The differences in the pharmacokinetics according to the 2 methods are presumably due to preferential tissue uptake of the l-form.
Similar content being viewed by others
References
Aaltonen L, Scheinin M (1982) Application of radioreceptor assay of benzodiazepines for toxicology. Acta Pharmacol Toxicol 50: 206–212
Adams RG, Verma P, Jackson AJ, Miller RL (1982) Plasma pharmacokinetics of intravenously administered atropine in normal human subjects. J Clin Pharmacol 22: 477–481
Berghem L, Bergman U, Schildt B, Sörbo B (1980) Plasma atropine concentrations determined by radioimmunoassay after single dose i.v. and i.m. administration. Br J Anaesth 52: 597–662
Gosselin RE, Gabourel JD, Wills JH (1960) The fate of atropine in man. Clin Pharmacol Ther 1: 597–604
Greenblatt DJ, Koch-Weser J (1975) Clinical pharmacokinetics. New Engl J Med 293: 702–706
Greene NM (1968) The metabolism of drug employed in anaesthesis 11. Anaesthesiology 29: 327–360
Gundert-Remy U, Schmidlin O, Hinderling PH (1980) Pharmacokinetics and pharmacodynamics of atropine in healthy humans. Naunyn-Schmiedeberg's Arch Pharmacol [Suppl] 311: 75
Iisalo E, Aaltonen L (1983) Antimuscarinic side-effects of disopyramide. Lancet 1: 996–997
Kalser SC (1971) The fate of atropine in man. Ann NY Acad Sci 179: 667–683
Kalser SC, McLain PL (1970) Atropine metabolism in man. Clin Pharmacol Ther 11: 214–217
Kanto J, Virtanen R, Iisalo E, Mäenpää K, Liukko P (1981) Placental transfer and pharmacokinetics of atropine after a single maternal intravenous and intramuscular administration. Acta Anaesth Scand 25: 85–88
Kawashima K, Levy A, Spector S (1976) Stereospecific radioimmunoassay for propranolol isomers. J Pharmacol Exp Ther 196: 517–523
Lowry DH, Rosebrough NJ, Farr AL, Randall RJ (1951) Protein measurement with the Folin phenol reagent. J Biol Chem 193: 265–275
Virtanen R, Kanto J, Iisalo E (1980) Radioimmunoassay for atropine and l-hyoscyamine. Acta Pharmacol Toxicol 47: 208–212
Virtanen R, Kanto J, Iisalo E, Iisalo EUM, Salo M, Sjövall S (1982) Pharmacokinetic studies on atropine with special reference to age. Acta Anaesth Scand 26: 297–300
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Aaltonen, L., Kanto, J., Iisalo, E. et al. Comparison of radioreceptor assay and radioimmunoassay for atropine: Pharmacokinetic application. Eur J Clin Pharmacol 26, 613–617 (1984). https://doi.org/10.1007/BF00543495
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00543495